KEY WORDS | photobiomodulation, Alzheimer, neuroscience |
CITY | Grenoble |
COUNTRY | France |
DETAILS OF THE OFFER | Working place: Fonds de dotation CLINATEC Missions: The benefits of photobiomodulation are multiple and its use can be extended to other disease models, including Alzheimer’s disease, the subject of the COVEA NEUROTEC project initiated in 2021 at the CLINATEC Endowment Fund and supervised by Professor John Mitrofanis, scientific director of FDD. Other pathologies and disease models being explored include postmyocardial infarction recovery, autism, traumatic brain injury and quality of sleep. The Clinatec FDD wishes to recruit a researcher with the ability and expertise to set-up and manage new projects, as well as to coordinate current developments and the various researchers. The appointee will conduct his project research under Professor John Mitrofanis direction and will be the key link between the post-doctoral staff and Professor John Mitrofanis.The development of relationships with institutional partners is also an area to be amplified in relation to photobiomodulation. The applicant must have a PhD in the fields of neuroscience, neurobiology or biotechnology. He/she must have previous experience in setting up pre-clinical or clinical projects and coordinating interdisciplinary teams. Experience in the field of photobiomodulation and/or in the general field of photonics is very much desired. The applicant must be motivated, autonomous, organised and comfortable in a multidisciplinary environment. He/she must have between 5 and 10 years of professional experience in the world of research. Neurocampus Graduate School (EUR UBGSNeuro).
|
TYPE OF JOB | Group leader |
TYPE OF CONTRACT | CDD (temporary / 2 years renewable) |
APPLICATION DEADLINE | 31 MAY 2023 |
employment START date | 1 JUN 2023 |